8 of 581 test positive; pause on Janssen lifted
Eight new cases of Covid-19 cases were identified out of 581 tests performed by the Department of Public Health and Social Services on Sunday, April 25, and from tests run by other labs between Friday, April 23 to Sunday, April 25.
Four cases reported recent travel history and were identified in quarantine. Three cases were identified through contact tracing.
To date, there have been a total of 7,923 officially reported Covid-19 cases with 136 deaths, 65 cases in active isolation, and 7,722 not in active isolation. The CAR Score is 0.7.
DPHSS conducted Covid-19 testing for staff and patrons of the A-Class Lounge and The Tsubaki Tower as part of two separate clusters reported at both establishments.
The following is a breakdown of samples collected from each testing outreach:
The DPHSS has resumed use of the Johnson and Johnson/Janssen (J&J/Janssen) vaccine following recommendations from the U.S. Centers for Disease Control and Prevention (CDC) and U.S. Food and Drug Administration (FDA) to lift the pause on the single-dose vaccine.
CDC and FDA have determined that the vaccine is safe and effective in preventing Covid-19.
The FDA has determined that the available data show that the vaccine’s known and potential benefits outweigh its known and potential risks in individuals 18 years of age and older.
At this time, the available data suggest that the chance of thrombosis-thrombocytopenia syndrome or TTS, a condition that causes low blood clots and low platelets, occurring is very low, but the FDA and CDC will remain vigilant in continuing to investigate this risk.
The pause was recommended earlier this month after reports of six cases of a rare and severe type of blood clot in individuals following administration of the Janssen vaccine.
Health care providers administering the vaccine and vaccine recipients or caregivers should review the Janssen Covid-19 vaccine fact sheet for vaccination providers and fact sheet for recipients and caregivers, which have been revised to include information about the risk of this syndrome, which has occurred in a very small number of people who have received the Janssen vaccine.